Phase 2 Narcolepsy Trial, Recruiting NCT06952699 Sponsor: Takeda Condition: Narcolepsy
Back to Narcolepsy

Phase 2 Narcolepsy Trial, Recruiting

NCT06952699
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You weigh at least 40 kilograms (about 88 pounds) and your body mass index (BMI) is between 16 and 38.
  • You have been officially diagnosed with Narcolepsy Type 2 (NT2).

Who may not be able to join:

  • You have another medical condition (besides NT2) that causes excessive daytime sleepiness.
  • You have a thyroid disease that your doctor considers medically significant.
  • You have been diagnosed with cancer in the last 5 years — although some exceptions may apply for certain stable, treated skin conditions, subject to approval by the trial's medical team (confirm with trial site).
  • You have tested positive for Hepatitis B, Hepatitis C, or HIV.
  • You have a significant history of head injury or head trauma.
  • You have a history of epilepsy, seizures, or convulsions — although a single fever-related seizure during childhood may not disqualify you (confirm with trial site).
  • You have a history of a stroke, a mini-stroke within the last 5 years, a brain aneurysm, or an abnormal connection between blood vessels in the brain.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Study Director, Takeda

Phone: +1-877-825-3327

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
6 May 2025
Est. completion
30 November 2026

Where this trial is recruiting

🇨🇳 China 🇫🇷 France 🇮🇹 Italy 🇯🇵 Japan 🇰🇷 South Korea 🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov